Drugs / Pegamotecan
Pegamotecan
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00080002 | Dec 2003 → ? | gastric cancer, gastroesophageal cancer | Enzon Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00079950 | Aug 2003 → ? | soft tissue sarcoma | Enzon Pharmaceuticals, Inc. | Suspended | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegamotecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00080002 ↗ |
| Known as | EZ-246 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989476 ↗ |
| Known as | PEG-Camptothecin | “Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction” NCT00080002 ↗1“Efficacy and Safety Evaluation of Pegamotecan (PEG-camptothecin) in Advanced or Metastatic Soft Tissue Sarcoma” NCT00079950 ↗ |
| Known as | Prothecan | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989476 ↗ |
| Modality | Small molecule | — CHEMBL3989476 ↗ |